BPC May 03 update

Alnylam ALNY shares lower on Sanofi SNY exit; Micro-cap Durect DRRX +49% on upcoming data release

Price and Volume Movers

AstraZeneca PLC (NYSE: AZN) announced the approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D).

Alnylam Pharmaceuticals (NASDAQ:ALNY) shares closed down 6% to $77.29 following reports that Sanofi (NASDAQ: SNY) is selling its stake in the company. This follows news in early April that the companies agreed to conclude their five-year alliance in rare genetic diseases.

DURECT Corporation (Nasdaq: DRRX) shares closed up 49% to $0.79 following news the microcap will report preliminary data from its Phase 2 trial of DUR-928 in patients with alcoholic hepatitis (AH), after the market close on Tuesday, May 7.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


IMV Inc. (IMV): $4.40; +19%.

Idera Pharmaceuticals, Inc. (IDRA): $3.57; +17%.

Anika Therapeutics, Inc. (ANIK): $39.22; +15%.

ImmunoGen, Inc. (IMGN): $2.88; +15%.

Sienna Biopharmaceuticals, Inc. (SNNA): $1.97; +13%.


Diffusion Pharmaceuticals Inc. (DFFN): $4.59; -22%.

ARCA biopharma, Inc. (ABIO): $10.90; -14%.

Emergent BioSolutions Inc. (EBS): $48.12; -10%.

Auris Medical Holding Ltd. (EARS): $4.82; -6%.

Seres Therapeutics, Inc. (MCRB): $5.04; -6%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ATNX – Athenex Inc.
Oraxol (Oral Paclitaxel)

Phase 2 Phase 2 presentation at ASCO May 29, 2020. Complete responses (CR) were observed in 27.3% of patients (6/22), partial responses (PR) were observed in 22.7% of patients (5/22),
$928.9 million

AZN – Astrazeneca PLC
Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)
Type 2 diabetes

Approved FDA approval announced May 3, 2019.
$144.3 billion

DRRX – DURECT Corporation
Alcoholic hepatitis (AH)

Phase 2b Phase 2b trial to commence 2H 2020.
$480.3 million

IMGN – ImmunoGen Inc.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer

Phase 1/2 Phase 1b/2 initial data at ASCO May 29, 2020 noted Overall Response Rate of 47%. Data from platinum-sensitive triplet cohort due fall of 2020.
$824.9 million

IMGN – ImmunoGen Inc.
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Phase 1 Phase 1 updated data at ASH December 9, 2019. AML ORR 54%; BPDCN 33%. Further data due at ASH December 5-8, 2020.
$824.9 million

IMV – IMV Inc.
DPX-Survivac and pembrolizumab
Diffuse Large Cell Lymphoma

Phase 2 Phase 2 top-line data due 2020.
$178.9 million

NVO – Novo Nordisk A/S
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes

Phase 2 Phase 2 data released 2Q 2019.
$151.1 billion

NVO – Novo Nordisk A/S
Somapacitan (NN8640)
Growth Hormone Deficiency (GHD)

Phase 3 Phase 3 trial initiated 2Q 2019.
$151.1 billion

NVO – Novo Nordisk A/S
Concizumab - Explorer 7
Hemophilia A

Phase 3 Phase 3 trial paused due to COVID-19.
$151.1 billion

ONCY – Oncolytics Biotech Inc.
Pelareorep and Tecentriq - AWARE-1
Breast cancer

Phase 1b Phase 1b final data due 2H 2020.
$88.4 million

ONCY – Oncolytics Biotech Inc.
Pelareorep and Carfilzomib /Dexamethasone
Multiple myeloma

Phase 1 Phase 1 interim data noted ORR 50% - May 29, 2020 at ASCO.
$88.4 million

RYTM – Rhythm Pharmaceuticals Inc.
POMC deficiency obesity / Leptin Receptor Deficiency Obesity

PDUFA priority review PDUFA date under priority review November 27, 2020.
$877.9 million

RYTM – Rhythm Pharmaceuticals Inc.
Alstrom Syndrome and Bardet-Biedl Syndrome

Phase 3 Phase 3 top-line data due 4Q 2020 or early 1Q 2021.
$877.9 million